Physician profile
Patrick C Chua
NPI 1043487937
$576.32
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2021: $16.74 · 2022: $90.22 · 2023: $17.70 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $115.73 | 2019 | |
| Fresenius USA Marketing, INC. | $111.36 | 2019-2024 | Velphoro |
| Vifor Pharma, INC. | $75.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $60.06 | 2022 | |
| Pfizer INC. | $32.72 | 2019 | |
| Shire North American Group INC | $30.43 | 2019 | |
| Baxter Healthcare | $25.92 | 2024 | Renal - Pd |
| Astrazeneca Pharmaceuticals Lp | $24.47 | 2019 | |
| Akebia Therapeutics INC | $19.89 | 2019 | |
| Scpharmaceuticals INC. | $18.00 | 2024 | |
| Calliditas Therapeutics US INC. | $17.32 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2019 | |
| Amgen INC. | $14.37 | 2024 | Tavneos |
| Horizon Therapeutics Plc | $13.59 | 2019 | |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.